钙调磷酸酶抑制剂再探讨：COVID-19 的新范式？
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
机构信息
University Hospital Zurich, Division of Pulmonology, Zurich, Switzerland; University of Zurich, Faculty of Medicine, Zurich, Switzerland.
University Hospital Zurich, Division of Pulmonology, Zurich, Switzerland; University of Zurich, Faculty of Medicine, Zurich, Switzerland.
出版信息
Braz J Infect Dis. 2020 Jul-Aug;24(4):365-367. doi: 10.1016/j.bjid.2020.06.005. Epub 2020 Jun 27.
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引起轻症、中症或重症疾病（COVID-19）。在重症疾病中，存在过度炎症反应，导致严重症状。严重 COVID-19 是一种免疫现象，而不是直接的病毒损伤疾病。COVID-19 的治疗均为试验性治疗。在重症疾病中，钙调神经磷酸酶抑制剂治疗可能有希望。本文基于实体器官移植受者 COVID-19 发病经验，解释钙调神经磷酸酶抑制剂治疗 COVID-19 的作用机制。
相似文献
1
Calcineurin inhibitors revisited: A new paradigm for COVID-19?钙调磷酸酶抑制剂再探讨：COVID-19 的新范式？
Braz J Infect Dis. 2020 Jul-Aug;24(4):365-367. doi: 10.1016/j.bjid.2020.06.005. Epub 2020 Jun 27.
2
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.环孢素作为新冠病毒感染的肾移植受者首选的钙调神经磷酸酶抑制剂。
Kidney Int. 2020 Aug;98(2):507-508. doi: 10.1016/j.kint.2020.05.024. Epub 2020 Jun 4.
3
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.移植受者感染 SARS-CoV-2 的药物治疗：治疗药物监测和药物相互作用的考虑因素。
Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761.
4
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究：一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
5
Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?用白细胞介素-6抑制剂治疗2019新型冠状病毒（COVID-19）：我们已经进展到那一步了吗？
Drug Discov Ther. 2020;14(2):100-102. doi: 10.5582/ddt.2020.03006.
6
Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.新冠病毒肺炎患者细胞因子风暴及细胞因子靶向治疗的危害：综述
J Med Internet Res. 2020 Aug 13;22(8):e20193. doi: 10.2196/20193.
7
Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center.美国一家大容量移植中心的 COVID-19 与实体器官移植的早期经验。
Transplantation. 2020 Nov;104(11):2208-2214. doi: 10.1097/TP.0000000000003339.
8
Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.盐酸杰克替尼治疗 COVID-19 患者细胞因子风暴的潜力。
Biosci Trends. 2020 Jul 17;14(3):161-167. doi: 10.5582/bst.2020.03106. Epub 2020 Jun 12.
9
Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).Rho激酶抑制剂对严重急性呼吸综合征冠状病毒2（COVID-19）治疗作用的合理性。
Pharmacol Res. 2020 Jun;156:104808. doi: 10.1016/j.phrs.2020.104808. Epub 2020 Apr 10.
10
Liver transplant immunosuppression during the covid-19 pandemic.新冠疫情期间的肝移植免疫抑制
Gastroenterol Hepatol. 2020 Oct;43(8):457-463. doi: 10.1016/j.gastrohep.2020.06.003. Epub 2020 Jun 12.
引用本文的文献
1
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.COVID-19 中巨噬细胞活化综合征有吸引力的治疗方法进展。
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
2
Liver Injury Associated with COVID-19 Infection: Pathogenesis, Histopathology, Prognosis, and Treatment.与新冠病毒感染相关的肝损伤：发病机制、组织病理学、预后及治疗
J Clin Med. 2023 Mar 6;12(5):2067. doi: 10.3390/jcm12052067.
3
The Outcome of COVID-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia: Single-Center Experience.沙特阿拉伯南部 COVID-19 感染对肾移植受者的影响：单中心经验。
Transplant Proc. 2023 Apr;55(3):521-529. doi: 10.1016/j.transproceed.2022.12.013. Epub 2023 Jan 9.
4
Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.用于管理 COVID-19 危重症患者的免疫调节治疗：一项叙述性综述。
World J Crit Care Med. 2022 Jul 9;11(4):269-297. doi: 10.5492/wjccm.v11.i4.269.
5
Calcineurin Inhibitors and COVID-19.钙调神经磷酸酶抑制剂与新型冠状病毒肺炎
Reumatol Clin (Engl Ed). 2022 May;18(5):314-315. doi: 10.1016/j.reumae.2020.09.007.
6
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.采用整合生物信息学方法，鉴定靶向 SARS-CoV-1 感染的宿主转录组可再利用药物，并通过 SARS-CoV-2 感染进行验证。
PLoS One. 2022 Apr 7;17(4):e0266124. doi: 10.1371/journal.pone.0266124. eCollection 2022.
7
Impact of COVID-19 Infection on Liver Transplant Recipients: Does It Make Any Difference?2019冠状病毒病感染对肝移植受者的影响：有何不同吗？
Cureus. 2022 Feb 28;14(2):e22687. doi: 10.7759/cureus.22687. eCollection 2022 Feb.
8
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.环孢素 A 通过三种 SARS-CoV-2 变体抑制肺细胞中的病毒感染和释放以及细胞因子产生。
Microbiol Spectr. 2022 Feb 23;10(1):e0150421. doi: 10.1128/spectrum.01504-21. Epub 2022 Jan 5.
9
The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的影响以及免疫抑制剂在感染2019冠状病毒病（COVID-19）的肾移植受者中的应用
Pharmaceuticals (Basel). 2021 Oct 17;14(10):1054. doi: 10.3390/ph14101054.
10
Coronavirus disease 2019 and renal transplantation.2019冠状病毒病与肾移植
World J Clin Cases. 2021 Sep 26;9(27):7986-7997. doi: 10.12998/wjcc.v9.i27.7986.
本文引用的文献
1
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
2
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下：一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
3
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.2019年非重症和重症冠状病毒病患者的治疗：循证指南
CMAJ. 2020 May 19;192(20):E536-E545. doi: 10.1503/cmaj.200648. Epub 2020 Apr 29.
4
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.COVID-19 患者的激肽释放酶-激肽系统阻断治疗以预防急性呼吸窘迫综合征。
Elife. 2020 Apr 27;9:e57555. doi: 10.7554/eLife.57555.
5
Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia.终末期新冠肺炎老年患者的肺移植
Ann Surg. 2020 Jul;272(1):e33-e34. doi: 10.1097/SLA.0000000000003955.
6
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.两例肺癌患者 2019 年新型冠状病毒（COVID-19）肺炎早期阶段的肺部病理学表现。
J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
7
MERS CoV infection in two renal transplant recipients: case report.两例肾移植受者中东呼吸综合征冠状病毒感染：病例报告。
Am J Transplant. 2015 Apr;15(4):1101-4. doi: 10.1111/ajt.13085. Epub 2015 Feb 25.
8
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.福莫司汀（FK506）可抑制人冠状病毒 SARS-CoV、HCoV-NL63 和 HCoV-229E 的复制。
Virus Res. 2012 Apr;165(1):112-7. doi: 10.1016/j.virusres.2012.02.002. Epub 2012 Feb 10.
Zotero 插件